THN 102 for excessive daytime sleepiness associated with Parkinson's disease: a phase 2a trial - Sorbonne Université
Journal Articles Movement Disorders Year : 2021

THN 102 for excessive daytime sleepiness associated with Parkinson's disease: a phase 2a trial

Björn Bosse
  • Function : Author
Werner Rein
  • Function : Author

Abstract

Background Excessive daytime sleepiness (EDS) is a frequent and disabling symptom of Parkinson's disease (PD) without approved treatment. THN102 is a novel combination drug of modafinil and low-dose flecainide. Objective The aim of this study is to evaluate the safety and efficacy of THN102 in PD patients with EDS. Methods The method involved a randomized, double-blind, placebo-controlled, crossover trial testing two doses of THN102 (200 mg/d modafinil with 2 mg/d [200/2] or 18 mg/d flecainide [200/18]) versus placebo; 75 patients were exposed to treatment. The primary endpoint was safety. The primary efficacy outcome was the change in Epworth Sleepiness Scale (ESS) score. Results Both doses of THN102 were well tolerated. ESS significantly improved with THN102 200/2 (least square means vs. placebo [95% confidence interval, CI]: −1.4 [−2.49; −0.31], P = 0.012) but did not change significantly with the 200/18 dosage. Conclusions THN102 was well tolerated and showed a signal of efficacy at the 200/2 dose, supporting further development for the treatment of EDS in PD. © 2021 International Parkinson and Movement Disorder Society
Fichier principal
Vignette du fichier
Corvol et al. - THN 102 for Excessive Daytime Sleepiness Associate.pdf (1.2 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03416717 , version 1 (05-11-2021)

Identifiers

Cite

Jean‐christophe Corvol, Jean‐philippe Azulay, Björn Bosse, Yves Dauvilliers, Luc Defebvre, et al.. THN 102 for excessive daytime sleepiness associated with Parkinson's disease: a phase 2a trial. Movement Disorders, 2021, ⟨10.1002/mds.28840⟩. ⟨hal-03416717⟩
128 View
282 Download

Altmetric

Share

More